B+
Bull case
20%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
TRLV
Trulieve CannabisCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
55%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+43.2
Score
AI commentary
The post-earnings signal is mixed: primary company reporting confirms weaker revenue and EBITDA trends but continued adjusted profitability, cash generation, and a buyback authorization. The available market snapshot showed the shares down about 2.8% on August 7. Analyst estimate revisions, target changes, and a verified consensus surprise comparison remain unavailable. Sparse coverage, the structural Harvest change, and insider selling support a monitoring posture rather than a directional thesis.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-07eventShare repurchase authorizationMedium impact
The company announced a repurchase program for up to the lesser of $50 million or 8,495,038 subordinate voting shares, providing a potential valuation and capital-allocation support. Execution timing and actual purchases remain unconfirmed. [#8-K-2026-08-07] [#IR-2026-08-07]
2026-08-07catalystMixed Q2 print creates near-term resetMedium impact
Q2 revenue was $271 million, down 6% sequentially and 10% year over year, versus the prior company expectation for low-single-digit sequential growth. Adjusted EBITDA was $98 million with a 36% margin, while adjusted net income remained $20 million. The $406 million GAAP loss mainly reflected a $407 million Harvest deconsolidation impact. [#SEC-8K-2026-05-07] [#8-K-2026-08-07] [#IR-2026-08-07]
2027-08-08catalystRescheduling and market-expansion optionalityHigh impact
Management cited DEA registration applications following medical-marijuana rescheduling, Georgia program expansion, pharmacy shipments, and broader expansion opportunities including Texas. Benefits remain conditional on regulatory implementation, demand, and execution. [#SEC-8K-2026-05-07] [#IR-2026-08-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology